Literature DB >> 11015741

Transient virus infection and multiple sclerosis.

G J Atkins1, S McQuaid, M M Morris-Downes, S E Galbraith, S Amor, S L Cosby, B J Sheahan.   

Abstract

Multiple sclerosis (MS) is a chronic, demyelinating disease of the CNS in which autoimmunity to myelin plays a role in pathogenesis. The epidemiology of MS indicates that it may be triggered by a virus infection before the age of adolescence, but attempts to associate a specific virus with MS have produced equivocal results. Many studies of the aetiology of MS have postulated that a persistent virus infection is involved, but transient virus infection may provide a plausible alternative mechanism that could explain many of the inconsistencies in MS research. The most studied animal model of MS is chronic relapsing experimental autoimmune encephalomyelitis (CREAE), which is induced in susceptible animals following injection of myelin components. While CREAE cannot provide information on the initiating factor for MS, it may mimic disease processes occurring after an initial trigger that may involve transient virus infection. The disease process may comprise separate triggering and relapse phases. The triggering phase may involve sensitisation to myelin antigens as a result of damage to oligodendrocytes or molecular mimicry. The relapse phase could be similar to CREAE, or alternatively relapses may be induced by further transient virus infections which may not involve infection of the CNS, but which may involve the recrudescence of anti-myelin autoimmunity. Although current vaccines have a high degree of biosafety, it is suggested that the measles-mumps-rubella vaccine in particular could be modified to obviate any possibility of triggering anti-myelin autoimmunity. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 11015741      PMCID: PMC7169221          DOI: 10.1002/1099-1654(200009/10)10:5<291::aid-rmv278>3.0.co;2-u

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  87 in total

1.  Death mechanisms in cultured cells infected by Semliki Forest virus.

Authors:  G M Glasgow; M M McGee; B J Sheahan; G J Atkins
Journal:  J Gen Virol       Date:  1997-07       Impact factor: 3.891

2.  Expression of sequence variants of endogenous retrovirus RGH in particle form in multiple sclerosis.

Authors:  T Christensen; P Dissing Sørensen; H Riemann; H J Hansen; A Møller-Larsen
Journal:  Lancet       Date:  1998-09-26       Impact factor: 79.321

3.  Antibody response to rubella virus structural proteins in multiple sclerosis.

Authors:  A Nath; J S Wolinsky
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

4.  Measles encephalomyelitis: lack of evidence of viral invasion of the central nervous system and quantitative study of the nature of demyelination.

Authors:  H E Gendelman; J S Wolinsky; R T Johnson; N J Pressman; G H Pezeshkpour; G F Boisset
Journal:  Ann Neurol       Date:  1984-04       Impact factor: 10.422

5.  The balance between persistent virus infection and immune cells determines demyelination.

Authors:  M Rodriguez; K D Pavelko; M K Njenga; W C Logan; P J Wettstein
Journal:  J Immunol       Date:  1996-12-15       Impact factor: 5.422

6.  In vivo depletion of CD8+ T cells prevents lesions of demyelination in Semliki Forest virus infection.

Authors:  I Subak-Sharpe; H Dyson; J Fazakerley
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Predisposition to EAE induction in resistant mice by prior infection with Semliki Forest virus.

Authors:  F Mokhtarian; P Swoveland
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

8.  Characterization of measles virus-induced cellular autoimmune reactions against myelin basic protein in Lewis rats.

Authors:  U G Liebert; G A Hashim; V ter Meulen
Journal:  J Neuroimmunol       Date:  1990 Sep-Oct       Impact factor: 3.478

9.  Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function.

Authors:  W Held; G A Waanders; H Acha-Orbea; H R MacDonald
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

Review 10.  Pathogenesis of virus-induced demyelination.

Authors:  J K Fazakerley; M J Buchmeier
Journal:  Adv Virus Res       Date:  1993       Impact factor: 9.937

View more
  7 in total

1.  Viral infection leading to brain dysfunction: more prevalent than appreciated?

Authors:  Anthony N van den Pol
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

2.  Neuroinflammation resulting from covert brain invasion by common viruses - a potential role in local and global neurodegeneration.

Authors:  Jeannine A Majde
Journal:  Med Hypotheses       Date:  2010-03-16       Impact factor: 1.538

3.  Deep sequencing for the detection of virus-like sequences in the brains of patients with multiple sclerosis: detection of GBV-C in human brain.

Authors:  John D Kriesel; Maurine R Hobbs; Brandt B Jones; Brett Milash; Rashed M Nagra; Kael F Fischer
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

4.  Spectrum of Microbial Sequences and a Bacterial Cell Wall Antigen in Primary Demyelination Brain Specimens Obtained from Living Patients.

Authors:  John D Kriesel; Preetida Bhetariya; Zheng-Ming Wang; David Renner; Cheryl Palmer; Kael F Fischer
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

5.  Spinal fluid IgG antibodies from patients with demyelinating diseases bind multiple sclerosis-associated bacteria.

Authors:  Emily Eckman; Jon D Laman; Kael F Fischer; Bert Lopansri; Tom B Martins; Harry R Hill; John D Kriesel
Journal:  J Mol Med (Berl)       Date:  2021-06-08       Impact factor: 4.599

Review 6.  Oligodendrogenesis in the normal and pathological central nervous system.

Authors:  Bilal El Waly; Magali Macchi; Myriam Cayre; Pascale Durbec
Journal:  Front Neurosci       Date:  2014-06-12       Impact factor: 4.677

7.  Enrichment of Retroviral Sequences in Brain Tissue from Patients with Severe Demyelinating Diseases.

Authors:  J D Kriesel; P J Bhetariya; B K Chan; T Wilson; K F Fischer
Journal:  J Emerg Dis Virol       Date:  2017-07-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.